MedTrace Logo

AZD8848 Single Ascending Dose Study

NCT01560234 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2016-06-06

Study results available
· View outcomes & findings →

Summary

This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of AZD8848 in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

AZD8848

Single dose, oral inhalation (nebuliser solution)

DRUG

Placebo

Single dose, oral inhalation (nebuliser solution)

Sponsors & Collaborators

Principal Investigators

  • Ajay Aggarwal · AstraZeneca R&D, 35 Gatehouse Drive, MA 02451 USA

  • James Ritter, BA,MA D Phil,BM BCh,MRCP,FRCP · Quintile Drug Research Unit at Guy's Hospital Quintiles Ltd 6 Newcomen Street London SE1 1YR United Kingdom

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01560234 on ClinicalTrials.gov